Five projects vie to become Brazil’s first national vaccine against Covid-19

More than ten projects are underway across the country, but five are more advanced. It is expected that Brazil will have at least one vaccine developed and produced domestically next year.

RIO DE JANEIRO, BRAZIL - Butanvac, which is being developed at the Butantan Institute and is already being tested in humans, is ahead in the race among some of Brazil's largest research institutions to find a national immunizing agent against Covid-19.

More than ten projects are underway across the country, five of which are more advanced. In addition to Butanvac, products from three federal research universities - UFRJ in Rio de Janeiro; UFMG in Belo Horizonte, Minas Gerais; and USP of Ribeirão Preto, São Paulo - are awaiting ANVISA (national health regulator) approval to begin clinical trials; UFPR in . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?